We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 10,000 results
  1. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia

    In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors (TKIs), especially in the absence of kinase domain...

    Jaeseung C. Kim, Michelle Chan-Seng-Yue, ... Faiyaz Notta in Nature Genetics
    Article Open access 19 June 2023
  2. Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study

    Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/ BCR::ABL1 , a distinct entity within the group of AML with defining genetic abnormalities,...

    Camille Gondran, Pierre-Yves Dumas, ... Sarah Bertoli in Blood Cancer Journal
    Article Open access 31 May 2024
  3. Role of BCR and FNBP1 Proteins in Phagocytosis as a Model of Membrane Rearrangements with Chronic Myelogenous Leukemia

    Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm resulting from the emergence of abnormal hematopoietic stem cells carrying a...

    S. V. Antonenko, D. S. Gurianov, ... G. D. Telegeev in Cytology and Genetics
    Article 27 July 2023
  4. Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study

    Objective

    Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia...

    Zahidah Abu Seman, Fadly Ahid, ... Yuslina Mat Yusoff in BMC Research Notes
    Article Open access 20 April 2024
  5. Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

    Background

    With the increased use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in cancer patients, adverse events (AEs) have garnered considerable...

    Dehua Zhao, **aoqing Long, Jisheng Wang in BMC Pharmacology and Toxicology
    Article Open access 23 February 2024
  6. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions

    Background

    Chronic myeloid leukaemia (CML) is one of the most well characterised human malignancies. Most patients have a cytogenetically visible...

    Philippa C. May, Alistair G. Reid, ... Andrew J. Innes in BMC Medical Genomics
    Article Open access 26 July 2023
  7. Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies

    The advent of BCR-ABL tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients....

    Sheng Sun, Jiqiu Qin, ... Shaoquan **ong in Cardiovascular Toxicology
    Article 21 July 2023
  8. Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia

    Abstract

    Chronic myelogenous leukemia (CML), a type of cancer of the white blood cells, arises due to the constitutive activity of the BCR-ABL1...

    Article 02 February 2023
  9. BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases

    Background

    BCR::ABL1 -like acute lymphoblastic leukaemia ( BCR::ABL1 -like ALL) is characterized by inferior outcomes. Current efforts concentrate on...

    Anna Płotka, Anna Przybyłowicz-Chalecka, ... Krzysztof Lewandowski in Molecular Cytogenetics
    Article Open access 03 July 2023
  10. Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing

    Background

    BCR::ABL1 fusion has significant prognostic value and is screened for chronic myeloid leukemia (CML) disease monitoring as a part of...

    Hyeonah Lee, Jieun Seo, ... Jong Rak Choi in Cancer Cell International
    Article Open access 29 May 2023
  11. Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population

    Background

    The role of familial influence in chronic myeloid leukaemia (CML) occurrence is less defined. Previously, we conducted a study to determine...

    Jew Win Kuan, Anselm Ting Su, ... Siow Phing Tay in BMC Cancer
    Article Open access 14 June 2024
  12. ‘Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting

    Background

    Early detection of BCR::ABL1 -like ALL could impact treatment management and improve the overall survival/outcome. BCR::ABL1 -like ALL cases...

    Dikshat Gopal Gupta, Neelam Varma, ... Subhash Varma in British Journal of Cancer
    Article 08 May 2023
  13. Long non-coding RNA PXN-AS1 promotes glutamine synthetase-mediated chronic myeloid leukemia BCR::ABL1-independent resistance to Imatinib via cell cycle signaling pathway

    Background

    Chronic myeloid leukemia (CML) is a common hematological malignancy, and tyrosine kinase inhibitors (TKIs) represent the primary...

    Yifei Li, Shiyi Yuan, ... Shifeng Lou in Cancer Cell International
    Article Open access 29 May 2024
  14. circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation

    Background

    The BCR-ABL fusion protein is the key factor that results in the occurrence of chronic myeloid leukemia (CML). Imatinib (IM) is a targeted...

    Jianming Wang, Yang Liang, ... Wenli Feng in Journal of Translational Medicine
    Article Open access 04 September 2022
  15. Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis

    The Philadelphia (Ph) chromosome was the first translocation identified in leukemia. It is supposed to be generated by aberrant ligation between two...

    Minori Tamai, Shinichi Fujisawa, ... Takeshi Inukai in Cancer Gene Therapy
    Article Open access 23 August 2022
  16. Novel CD81 Mutations in a Chinese Patient Led to IgA Nephropathy and Impaired BCR Signaling

    Purpose

    CD81 deficiency is an extremely rare primary immunodeficiency disease characterized by severe and recurrent infections, IgA-related...

    Lu Yang, ** Liu, ... **aodong Zhao in Journal of Clinical Immunology
    Article 18 July 2022
  17. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation

    Background

    BCR-ABL-independent drug resistance is a barrier to curative treatment of chronic myeloid leukemia (CML). However, the molecular pathways...

    Taewoo Yang, Kyu-Young Sim, ... Sung-Gyoo Park in Journal of Experimental & Clinical Cancer Research
    Article Open access 03 March 2022
  18. A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript

    Background

    Acute lymphoblastic leukemia is the most common type of cancer in children. Most often it affects the age group between 2 and 5 years of...

    Aleksandra Mroczkowska, Bożena Jaźwiec, ... Tomasz Wróbel in BMC Medical Genomics
    Article Open access 05 February 2022
  19. Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India

    Highly polymorphic BCR-ABL kinase domains have been reported to harbor more than a hundred mutations, and among these, 40–60% have been identified as...

    Gautam Hazarika, Manash Jyoti Kalita, ... Subhash Medhi in Biochemical Genetics
    Article 16 February 2024
Did you find what you were looking for? Share feedback.